- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in immunotherapy for hepatocellular carcinoma
Authors
Keywords
-
Journal
Nature Reviews Gastroenterology & Hepatology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-13
DOI
10.1038/s41575-021-00438-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase
- (2020) Olivier Vollmer et al. AUTOIMMUNITY REVIEWS
- Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
- (2020) Parisa Malekzadeh et al. CLINICAL CANCER RESEARCH
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Repurposing infectious disease vaccines for intratumoral immunotherapy
- (2020) Ignacio Melero et al. Journal for ImmunoTherapy of Cancer
- Immune checkpoint signaling and cancer immunotherapy
- (2020) Xing He et al. CELL RESEARCH
- Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
- (2020) Thoetchai (Bee) Peeraphatdit et al. HEPATOLOGY
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
- (2020) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
- (2020) B. Sangro et al. ANNALS OF ONCOLOGY
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy
- (2020) Enric Vercher et al. JOURNAL OF HEPATOLOGY
- Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors
- (2020) Iván Márquez-Rodas et al. Science Translational Medicine
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
- (2020) John D. Gordan et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
- (2020) Jordi Rimola et al. EUROPEAN JOURNAL OF RADIOLOGY
- WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
- (2019) Jason J. Luke et al. CLINICAL CANCER RESEARCH
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
- (2019) Bernhard Scheiner et al. United European Gastroenterology Journal
- Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
- (2019) Parisa Malekzadeh et al. JOURNAL OF CLINICAL INVESTIGATION
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells
- (2019) Ming Zhong et al. BMC CANCER
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
- (2019) Fangjun Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
- (2019) Linda Hammerich et al. NATURE MEDICINE
- Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
- (2019) Daisuke Sugiura et al. SCIENCE
- Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
- (2019) Jasmine Davda et al. Journal for ImmunoTherapy of Cancer
- Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
- (2019) Lynn G. Feun et al. CANCER
- Capecitabine in advanced hepatocellular carcinoma: A multicenter experience
- (2019) Filippo Pelizzaro et al. DIGESTIVE AND LIVER DISEASE
- STING pathway agonism as a cancer therapeutic
- (2019) Blake A. Flood et al. IMMUNOLOGICAL REVIEWS
- Vascular Targets for the Treatment of Portal Hypertension
- (2019) Ksenia Brusilovskaya et al. SEMINARS IN LIVER DISEASE
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
- (2019) Marina Ruiz de Galarreta et al. Cancer Discovery
- The TNF Paradox in Cancer Progression and Immunotherapy
- (2019) Anne Montfort et al. Frontiers in Immunology
- Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC
- (2019) Kohei Shigeta et al. HEPATOLOGY
- Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles
- (2019) Claire Vanpouille-Box et al. NATURE REVIEWS DRUG DISCOVERY
- Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation
- (2019) Pedro Berraondo et al. Cancer Discovery
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- LBA39Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
- (2019) M Lee et al. ANNALS OF ONCOLOGY
- 325PAssociation between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
- (2019) L Wong et al. ANNALS OF ONCOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
- (2019) Liang-qing Dong et al. JOURNAL OF HEPATOLOGY
- Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
- (2019) Maria Esperanza Rodriguez-Ruiz et al. NATURE IMMUNOLOGY
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- (2019) Jianchun Duan et al. JAMA Oncology
- Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
- (2018) M E Rodríguez-Ruiz et al. ANNALS OF ONCOLOGY
- Defective HLA class I antigen processing machinery in cancer
- (2018) Lei Cai et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
- (2018) Zachary J. Brown et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Exploring the role of oncolytic viruses in hepatobiliary cancers
- (2018) Pavan Tenneti et al. Immunotherapy
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EG FR -Mutant Lung Adenocarcinoma
- (2018) Po-Hao Feng et al. Journal of Thoracic Oncology
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity
- (2018) Shishir Shetty et al. Nature Reviews Gastroenterology & Hepatology
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
- (2018) Michäel Duruisseaux et al. Lancet Respiratory Medicine
- Potentiating cancer vaccine efficacy in liver cancer
- (2018) Maria Tagliamonte et al. OncoImmunology
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Ecto-5′-nucleotidase (CD73) is a potential target of hepatocellular carcinoma
- (2018) Shalaimaiti Shali et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy
- (2018) Melody Smith et al. OncoImmunology
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- AASLD guidelines for the treatment of hepatocellular carcinoma
- (2017) Julie K. Heimbach et al. HEPATOLOGY
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
- (2017) Masao Omata et al. Hepatology International
- Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
- (2017) Nicole Glodde et al. IMMUNITY
- Alarmins and immunity
- (2017) De Yang et al. IMMUNOLOGICAL REVIEWS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- (2017) Paolo A Ascierto et al. LANCET ONCOLOGY
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
- (2017) Marta Łuksza et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients
- (2017) Li Peng et al. Oncotarget
- Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
- (2017) Zhiwu Jiang et al. Frontiers in Immunology
- Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
- (2017) Mirjana Efremova et al. Frontiers in Immunology
- Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
- (2016) Emeric Limagne et al. CANCER RESEARCH
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Liver-infiltrating CD11b−CD27− NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression
- (2016) Qiong-Fang Zhang et al. Cellular & Molecular Immunology
- Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
- (2016) Shao-Lai Zhou et al. GASTROENTEROLOGY
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally
- (2016) M. Angela Aznar et al. JOURNAL OF IMMUNOLOGY
- Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection
- (2016) Xiao-Yan Cai et al. MEDICINE
- Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
- (2016) Zhu Li et al. MEDICINE
- Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer
- (2016) Akihiro Fujimoto et al. NATURE GENETICS
- Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
- (2016) Emilie M.J. van Brummelen et al. ONCOLOGIST
- Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma
- (2016) Stefani Spranger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression
- (2016) X. Xiao et al. Cancer Discovery
- TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype
- (2016) Fan Zhang et al. Oncotarget
- Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments
- (2016) Elisabetta Cariani et al. OncoImmunology
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Tumor-infiltrating lymphocyte activity is enhanced in tumors with low IL-10 production in HBV-induced hepatocellular carcinoma
- (2015) Yang Shi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Developments in cancer vaccines for hepatocellular carcinoma
- (2015) Luigi Buonaguro et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- High Serum Transforming Growth Factor- 1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2015) T.-H. Lin et al. CLINICAL CANCER RESEARCH
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
- (2015) Joon Hyeok Lee et al. GASTROENTEROLOGY
- Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
- (2015) Wenjiang Yan et al. GUT
- Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma
- (2015) Juling Ji et al. HEPATOLOGY
- Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma
- (2015) Oscar W.H. Yeung et al. JOURNAL OF HEPATOLOGY
- The yin and yang of evasion and immune activation in HCC
- (2015) Oxana V. Makarova-Rusher et al. JOURNAL OF HEPATOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma
- (2015) Longhao Sun et al. TUMOR BIOLOGY
- Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
- (2015) A. R. Sanchez-Paulete et al. Cancer Discovery
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma
- (2015) Shan-Shan Jiang et al. Oncotarget
- Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
- (2014) M. F. Sanmamed et al. CLINICAL CANCER RESEARCH
- Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
- (2014) H. Gao et al. CLINICAL CANCER RESEARCH
- Enhanced suppressor function of TIM-3+FoxP3+regulatory T cells
- (2014) Anne-Sophie Gautron et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
- (2014) Masatoshi Kudo et al. HEPATOLOGY
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Tumor-Derived α-Fetoprotein Impairs the Differentiation and T Cell Stimulatory Activity of Human Dendritic Cells
- (2014) Angela D. Pardee et al. JOURNAL OF IMMUNOLOGY
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
- (2013) Fumitaka Arihara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus-Related Hepatocellular Carcinoma
- (2013) E. Cariani et al. CLINICAL CANCER RESEARCH
- HLA ligandome tumor antigen discovery for personalized vaccine approach
- (2013) Hans-Georg Rammensee et al. Expert Review of Vaccines
- Human CD14+CTLA-4+regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma
- (2013) Yanmei Han et al. HEPATOLOGY
- Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma
- (2013) Tobias Flecken et al. HEPATOLOGY
- Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1
- (2013) Wing-Kee Lee et al. INTERNATIONAL JOURNAL OF CANCER
- Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
- (2013) C. Andrew Stewart et al. JOURNAL OF CLINICAL INVESTIGATION
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion
- (2013) Bastian Höchst et al. JOURNAL OF HEPATOLOGY
- Hepatic Stellate Cells Preferentially Induce Foxp3+ Regulatory T Cells by Production of Retinoic Acid
- (2013) R. M. Dunham et al. JOURNAL OF IMMUNOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Improved affinity AFP-specific T cell receptor for hepatocellular carcinoma
- (2013) Andrew B Gerry et al. Journal for ImmunoTherapy of Cancer
- A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
- (2012) Tim F Greten et al. BMC CANCER
- Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
- (2012) Y. Sawada et al. CLINICAL CANCER RESEARCH
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma
- (2012) Eishiro Mizukoshi et al. HEPATOLOGY
- The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner
- (2012) Yong Yi et al. JOURNAL OF HEPATOLOGY
- Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses
- (2012) F. Zhao et al. JOURNAL OF IMMUNOLOGY
- Efficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) V. Boige et al. ONCOLOGIST
- Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma Patients
- (2011) Sarah M. Bray et al. Clinical & Developmental Immunology
- Cross-presentation of antigen by diverse subsets of murine liver cells
- (2011) Mohammad R. Ebrahimkhani et al. HEPATOLOGY
- Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence
- (2011) Hiroteru Kamimura et al. JOURNAL OF HEPATOLOGY
- Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis
- (2011) Kang-Jie Chen et al. PLoS One
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Safety of Bevacizumab in Patients with Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials
- (2010) S. Geiger-Gritsch et al. ONCOLOGIST
- Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
- (2010) N. Jain et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Liver as a Lymphoid Organ
- (2009) Ian Nicholas Crispe Annual Review of Immunology
- Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
- (2009) K. Wu et al. CANCER RESEARCH
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
- (2009) Bastian Hoechst et al. HEPATOLOGY
- Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients
- (2009) Jia Zhou et al. INTERNATIONAL JOURNAL OF CANCER
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
- (2009) Dong-Ming Kuang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
- (2009) Thomas Reiberger et al. JOURNAL OF HEPATOLOGY
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2008) Abby B. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now